All authors meet the ICMJE authorship criteria.
Introduction
It has been shown that neuraminidase inhibitors (NAIs) can alleviate the major symptoms of uncomplicated influenza A and B and reduce the duration by approximately 1 to 1.5 days when administered within 48 hours of onset of illness compared with the effect of a placebo [1] [2] [3] [4] . NAIs reduce the incidence of acute otitis media in children aged one to five years who are suffering from seasonal influenza [5] and contribute to survival benefit in patients infected with influenza A(H1N1)pdm09 virus [6] . In Japan, almost all patients with an influenza-like illness are tested with rapid antigen tests, and they are treated with one of the NAIs when positive; this has become standard practice in clinics nationwide [7] . The clinical effectiveness of zanamivir, laninamivir, and peramivir has been tested mainly in clinical trials compared to the effect of either a placebo or oseltamivir [1, [8] [9] [10] [11] [12] [13] [14] , and there have been few studies in which the clinical effectiveness of four NAIs (oseltamivir, zanamivir, laninamivir, and peramivir) was compared [15, 16] . In the present study, we evaluated the clinical effectiveness of the four NAIs for children with influenza A and B by comparing the durations of fever after administration of the first doses of NAIs.
PATIENTS AND METHODS

Patients
Outpatients aged 0 months to 18 years who had an axillary temperature of 37.5°C or higher were diagnosed as having influenza virus infection based on results obtained by a rapid antigen test. Patients were excluded from this study if the time from onset of fever to initiating administration was 48 hours or more or if body temperature fell to less than 37.5°C before starting administration. Patients who had bacterial infections (pneumonia, otitis media) were excluded. Patients diagnosed as having influenza were treated with one of the NAIs (oseltamivir, zanamivir, laninamivir, and peramivir) after obtaining informed consent from the children's parents. The decision regarding administration of NAIs was left to the discretion of the physician. Oseltamivir was administered at 2 mg/kg/dose (to a maximum of 75 mg/dose) twice daily for 5 days, zanamivir was administered by inhalation at 10 mg/dose twice daily for 5 days, laninamivir was administered as a single inhalation (20 mg for patients less than 10 years of age and 40 mg for patients 10 years of age or more) and peramivir was administered intravenously at 10 mg/kg once daily (to a maximum of 600 mg/dose).
Study procedures
A prospective, multicenter observational study was conducted in the 2014-2015, 2015-2016 and 2016-2017 influenza seasons at 25 pediatric clinics and in departments of pediatrics in 11 hospitals in Hokkaido, Japan.
The age and sex of each patient and the date and results of the rapid diagnostic test were recorded by physicians. The time of onset (the first time that the patient had a fever of more than 37.5°C), vaccination status, selection of NAIs, date and time of first administration of NAIs, and total number of administrations of NAIs were recorded by the parents of children. The parents were also instructed to take their children's axillary body temperatures at least four times daily and to plot the body temperatures on a graph with temperature on the vertical axis and time on the horizontal axis. The time at which a temperature of less than 37.5°C was attained and maintained for more than 48 hours was defined as the time when the patient became afebrile. If a patient's temperature decreased to less than 37.5°C and remained less than 37.5°C for more than 24 hours but later increased to more than 37.5°C, the patient was considered to have biphasic fever. All ethical approval for this study was obtained from the Institutional Review Board of Hokkaido University Hospital for Clinical Research (014-0172).
Real-time reverse transcription PCR
Real-time reverse transcription PCR for detection of influenza A and B viruses
was performed according to the referenced protocol [17] .
Power calculation and statistical analysis
To detect a difference of 10% (from 50% to 40%) in the proportions of patients receiving NAIs whose temperature was less than 37.5°C at 24 hours after onset, 70% of the statistical power would be obtained with a two-sided alpha of 5% and the log-rank test of a pair-wise comparison without multiplicity adjustment if 300 patients (1200 patients in total) could be enrolled for each NAI group.
In the primary analysis, the distributions of fever duration were depicted by the Kaplan-Meier method and the log-rank test was used for comparisons of estimated fever duration in each NAI group. To adjust for confounding, we set the duration of fever as a dependent variable and set the following factors as clinically relevant independent variables in multivariate Cox regression analysis: type of NAI, age, sex, vaccination status, and time from onset to first dose of the NAI. The Wald test was performed on statistical significance testing for the adjusted hazard ratio in the Cox regression analysis. For the analysis of episodes of biphasic fever, a logistic regression model was used to determine factors (age, sex, anti-influenza drug, type of influenza, vaccination, and time from onset to administration) influencing the episodes of biphasic fever with Firth's method [18] . No multiplicity adjustment was performed in the analyses.
In this study, the selection of NAIs was unbalanced among age groups (Table 1, supplemental Table 1 ). There are at least three reasons for the unbalanced selection of NAIs. First, the two inhalation NAIs, zanamivir and laninamivir, are mainly prescribed for teenagers [19] . Second, in March 2007, Japan's Ministry of Health, Labor and Welfare (MHLW) issued a warning against the use of oseltamivir in teenagers, except for those at high risks, after reports of two suicides by teenagers shortly after ingestion of oseltamivir [20] . Third, peramivir is mainly administered to adult and elderly patients who are admitted to a hospital and are able to tolerate intravenous administration [19] . For these reasons, the results were analyzed separately by three age groups (0-4 years, 5-9 years and 10-18 years) to avoid a selection bias in addition to analysis of the results for all patients without stratification by age group.
A two-sided p value of <0.05 was considered statistically significant. All statistical analyses were performed using JMP software version 13.0.0 (SAS Institute, Cary, NC, USA).
RESULTS
Study population
A total of 1207 patients who were otherwise healthy were enrolled in this study. Table 1 . The NAIs used in patients with influenza A and B in the three age groups are summarized in supplemental Table 1 .
Influenza virus typing
Of the 747 influenza A-positive and 460 B-positive samples by the rapid antigen test, 658 and 420 samples were tested by real-time reverse transcription PCR using type-specific primers, respectively, and were confirmed to be influenza A and B viruses, respectively.
Durations of fever after administration of the first doses of NAIs in all patients without stratification by age group
Kaplan-Meier estimates for duration of fever after administration of the first dose of the NAI were stratified by age groups (Fig. 1) . Log-rank tests demonstrated statistically significant differences in duration of fever after administration of the first dose of the NAI among age groups (p = 0.012 for influenza A and p<0.001 for influenza B). Kaplan-Meier estimates for duration of fever after administration of the first dose of each of the four NAIs stratified by age groups are shown in supplemental Fig. 1 .
The Cox proportional-hazards model showed that the duration of fever after administration of the first dose of the NAI was shorter in older patients (hazard ratio = 1.06 per 1 year of age, p<0.001) and that the duration of fever after administration of the first dose of the NAI was shorter in patients with influenza A infection than in patients with influenza B infection (hazard ratio = 2.21, p<0.001) ( Table 2 ).
Durations of fever after administration of the first doses of NAIs in all patients stratified by age group
As explained in the statistical methods, the results were analyzed separately by three age groups to avoid a selection bias. In the 0-4 years of age group, Kaplan-Meier curves showed that the duration of fever after administration of the first dose of the NAI was shorter in patients with influenza A infection than in patients with influenza B infection ( Figs. 2A and 2B ). This association was similar in the multivariate Cox regression model (hazard ratio = 2.60, p<0.001; Table 3 ). The duration of fever after administration of the first dose of the NAI in patients whose time from onset of influenza virus infection to administration of NAIs was more than 24 hours was shorter than that in patients whose time from onset of influenza virus infection to administration of NAIs was less than 12 hours (hazard ratio = 1.40, p = 0.046). There was no statistically significant association between duration of fever following commencement of treatment and choice of NAI (oseltamivir or peramivir), sex or vaccination status (Table 3 ). There was no statistically significant difference between oseltamivir and peramivir in the Kaplan-Meier curves for the duration of fever after administration of the first dose of the NAI in all of the patients with influenza A or B ( Fig. 3A ), in patients with influenza A (Fig. 3B ) or in patients with influenza B (Fig.   3C ).
In the 5-9 years of age group, Kaplan-Meier curves showed that the duration of fever after administration of the first dose of the NAI was shorter in patients with influenza A infection than in patients with influenza B infection (Figs. 2C, 2D, 2E and 2F). This association was similar in the multivariate Cox regression model (hazard ratio = 2.32, p<0.001; Table 3 ). There was no statistically significant difference between NAIs in the Kaplan-Meier curves for the duration of fever after administration of the first dose of the NAI in all of the patients with influenza A or B ( Fig. 3D ), in patients with influenza A (Fig. 3E ) or in patients with influenza B (Fig. 3F ). However, multivariate Cox regression analysis showed that the duration of fever after administration of the first dose of the NAI was shorter in patients treated with oseltamivir (hazard ratio = 1.27, p = 0.048), peramivir (hazard ratio = 1.35, p = 0.049) or zanamivir (hazard ratio = 1.33, p = 0.023) than in patients treated with laninanivir ( Table 3 ). The duration of fever after administration of the first dose of laninamivir showed no statistically significant difference between 106 patients (90.6%) who inhaled laninamivir at a pharmacy and 11 patients (9.4%) who inhaled laninamivir at home in the 5-9 years of age group (log-rank test: χ 2 = 0.40, d.f. = 1, p = 0.525). There was no statistically significant association between duration of fever following commencement of treatment and time from onset of influenza virus infection to administration of NAIs, sex (p = 0.597) or vaccination status (p = 0.089).
In the 10-18 years of age group, Kaplan-Meier curves showed that the duration of fever after administration of the first dose of the NAI was shorter in patients with influenza A infection than in patients with influenza B infection (Figs. 2H and 2I) except for the patients administered oseltamivir or peramivir (Figs. 2G and 2J). These statistically non-significant results were considered to be due to the small number of influenza B-infected patients aged 10-18 years who were administered oseltamivir (n=2) or peramivir (n=7). In the multivariate Cox regression model, the duration of fever after administration of the first dose of the NAI was shorter in patients with influenza A infection than in patients with influenza B infection (hazard ratio = 1.75, p<0.001; Table 3 ). The durations of fever after administration of the first dose of each of the four NAIs in influenza A-infected patients and influenza B-infected patients aged 10-18 years were shown separately by Kaplan-Meier estimates (Figs. 3G, 3H and 3I).
Multivariate Cox regression analysis showed that the duration of fever after administration of the first dose of the NAI was shorter in patients treated with oseltamivir than in patients treated with zanamivir (hazard ratio = 1.91, p = 0.031; Table 3 ). There was no statistically significant association between duration of fever following commencement of treatment and time from onset of influenza virus infection to administration of NAIs, sex (p = 0.672) or vaccination status (p = 0.147).
Episodes of biphasic fever
Biphasic fever occurred in 9 (4.6%) of the 197 influenza A-infected patients and (Table 4 ). These patients did not have infectious complications such as pneumonia or acute otitis media. The logistic regression model showed that the number of biphasic fever episodes was 2.99-times greater for influenza B-infected patients than for influenza A-infected patients (p<0.001) ( Supplemental table 3 ). The number of biphasic fever episodes in influenza A-or B-infected patients aged 0-4 years was 2.89-times greater than that in patients aged 10-18 years (p = 0.010), and the number of episodes in influenza A-or Binfected patients aged 5-9 years was 2.13-times greater than that in patients aged 10-18 years (p = 0.012). The choice of NAIs was weakly correlated with the number of biphasic fever episodes in influenza A-infected patients. The logistic regression model for factors influencing episodes of biphasic fever showed no statistically significant differences in time from onset to administration of NAIs, sex and vaccination. The frequencies of biphasic fever in influenza A-and influenza B-infected patients in each age group were evaluated separately by the logistic regression model ( Supplemental   table 4 ).
DISCUSSION
In the present study, we evaluated the clinical effectiveness of four NAIs for influenza A and B virus infections by comparing the durations of fever after administration of the first doses of NAIs. In the 0-4 years of age group, the duration of fever after administration of the first dose of the NAI showed no statistically significant difference between patients administered oseltamivir and those administered peramivir ( Table 3 ). Although there have been several clinical studies concerning oseltamivir and peramivir [15, 16, 21, 22] , the present study is the first study in which the clinical effectiveness of oseltamivir and that of peramivir were compared in influenza-infected patients aged 0-4 years. In the 5-9 years of age group, the duration of fever after administration of the first dose of the NAI was shorter in patients treated with oseltamivir, zanamivir or peramivir than in patients treated with laninamivir. In patients infected with influenza A virus, the duration of fever after administration of the first dose of either oseltamivir or peramivir was shorter than that in patients treated with laninamivir. Contrary to our results, the clinical effectiveness of laninamivir has been reported to be almost the same as that of oseltamivir in pediatric patients infected with influenza A(H3N2) and influenza B viruses [11, 16] and in adult patients infected with influenza A(H3N2) and influenza A(H1N1) viruses carrying the H274Y mutation [12] . Incomplete delivery of laninamivir might partially explain the delay of defervescence in the 5-9 years of age group. In the 10-18 years of age group, the duration of fever after administration of the first dose of the NAI was shorter in influenza A-infected patients treated with oseltamivir than in those treated with zanamivir. It has been reported that the mean duration of fever was significantly shorter in influenza A(H3N2)-infected patients treated with oseltamivir than in those treated with zanamivir [23] . ** The duration of fever after administration of the first dose of the NAI was shorter in patients whose time from onset of influenza virus infection to administration of the NAI was longer.
*** In the 5-9 years of age group, the duration of fever after administration of the first dose of oseltamivir was shorter than that after administration of the first dose of laninamivir in patients with influenza A infection. The duration of fever after administration of the first dose of peramivir was shorter than that after administration of the first dose of laninamivir in patients with influenza A infection. The duration of fever after administration of the first dose of zanamivir was shorter than that after administration of the first dose of laninamivir in patients with influenza A or B infection. **** In the 10-18 years of age group, the duration of fever after administration of the first dose of oseltamivir was shorter than that after administration of the first dose of zanamivir in patients with influenza A infection. ** The number of biphasic fever episodes in influenza A-or B-infected patients aged 0-4 years was 2.89-times greater than that in patients aged [10] [11] [12] [13] [14] [15] [16] [17] [18] years, and the number of biphasic fever episodes in influenza B-infected patients aged 0-4 years was 5.83-times greater than that in patients aged 10-18
years.
*** The number of biphasic fever episodes in influenza A-or B-infected patients aged 5-9 years was 2.13-times greater than that in patients aged [10] [11] [12] [13] [14] [15] [16] [17] [18] years, and the number of biphasic fever episodes in influenza B-infected patients aged 5-9 years was 5.11-times greater than that in patients aged 10-18 years.
**** The number of biphasic fever episodes in influenza A-infected patients treated with laninamivir was 4.19-times greater than that in patients treated with peramivir, and the number of biphasic fever episodes in influenza A-infected patients treated with zanamivir was 3.77-times greater than that in patients treated with peramivir. ** In the 5-9 years of age group, the number of biphasic fever episodes in patients infected with influenza B virus was 4.34-times greater than that in patients infected with influenza A virus.
